Capnia

Capnia, Essentialis merge to create rare disease therapeutics company

Monday, January 2, 2017

Capnia and privately held Essentialis have announced their entry into a definitive merger agreement to create a rare disease therapeutics company. The combined company will be well-positioned to advance diazoxide choline controlled release tablet (DCCR), a once-daily oral tablet for the treatment of patients with Prader-Willi syndrome (PWS). PWS is a rare complex genetic neurobehavioral/metabolic disease. The clinical features of the disease include hyperphagia (unrelenting hunger), as well as metabolic, endocrine, cognitive and behavioral complications resulting in significant morbidity and premature death.

[Read More]

Court recognizes majority of Viropro shareholders’ election of new board of directors

Friday, June 6, 2014

Viropro, a Nevada corporation that was formed to specialize in contract research, development and manufacturing of biotherapeutic proteins for including cancer, diabetes, inflammation and hepatitis, has a new board of directors as a result of an order of the Supreme Court of the State of New York in a challenge by a majority of the Viropro shareholders to the management of Viropro.

[Read More]